inPractice® - Oral Pre-Exposure Prophylaxis

FDA approved emtricitabine/tenofovir DF to reduce the risk of sexually acquired HIV infection in adults at high risk in 2012 based on favorable results from several studies^{[Grant 2010; Baeten 2012; Thigpen 2012]}
Several clinical trials have established the efficacy of tenofovir DF–containing PrEP
In 2018, FDA expanded indication for oral emtricitabine/tenofovir DF PrEP to include at-risk adolescents when used in combination with safer sex practices^{[FDA FTC TDF]}